Martin Götte Selected Research

xylosylprotein 4-beta-galactosyltransferase

4/2008	Changes in heparan sulfate are associated with delayed wound repair, altered cell migration, adhesion and contractility in the galactosyltransferase I (beta4GalT-7) deficient form of Ehlers-Danlos syndrome.
7/2006	Defective glycosylation of decorin and biglycan, altered collagen structure, and abnormal phenotype of the skin fibroblasts of an Ehlers-Danlos syndrome patient carrying the novel Arg270Cys substitution in galactosyltransferase I (beta4GalT-7).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Götte Research Topics

Disease

52	Neoplasms (Cancer) 05/2022 - 01/2006
42	Breast Neoplasms (Breast Cancer) 10/2022 - 04/2005
14	Inflammation (Inflammations) 05/2022 - 04/2002
14	Endometriosis 03/2022 - 03/2013
10	Neoplasm Metastasis (Metastasis) 05/2022 - 09/2006
10	Carcinogenesis 01/2021 - 01/2007
8	Carcinoma (Carcinomatosis) 01/2022 - 01/2006
8	Triple Negative Breast Neoplasms 01/2022 - 01/2013
8	Inflammatory Breast Neoplasms 01/2021 - 01/2017
5	Hypersensitivity (Allergy) 01/2020 - 04/2009
4	Ovarian Neoplasms (Ovarian Cancer) 12/2022 - 07/2021
4	Wounds and Injuries (Trauma) 01/2021 - 10/2004
3	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 10/2011
3	Pathologic Processes 01/2021 - 11/2004
3	Ehlers-Danlos Syndrome (Syndrome, Ehlers-Danlos) 04/2008 - 02/2005
2	Noninfiltrating Intraductal Carcinoma (DCIS) 10/2022 - 01/2007
2	Necrosis 03/2022 - 01/2021
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2022 - 07/2021
2	Disease Progression 07/2021 - 11/2014
2	Colonic Neoplasms (Colon Cancer) 01/2021 - 01/2020
2	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 05/2020
2	Cysts 10/2020 - 01/2013
2	Brain Neoplasms (Brain Tumor) 05/2020 - 01/2019
2	Colitis 01/2017 - 01/2010
1	Serous Cystadenocarcinoma 05/2022
1	Hodgkin Disease (Hodgkin's Disease) 07/2021
1	Chronic Disease (Chronic Diseases) 01/2021

Drug/Important Bio-Agent (IBA)

28	Syndecan-1 (Syndecan 1)IBA 10/2022 - 04/2002
16	MicroRNAs (MicroRNA)IBA 10/2021 - 09/2012
14	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA 05/2022 - 10/2004
13	Small Interfering RNA (siRNA)IBA 12/2022 - 09/2012
11	Proteoglycans (Proteoglycan)IBA 10/2022 - 01/2007
11	Biomarkers (Surrogate Marker)IBA 07/2021 - 07/2014
11	Heparitin Sulfate (Heparan Sulfate)IBA 01/2021 - 04/2003
10	Messenger RNA (mRNA)IBA 12/2022 - 04/2005
8	Proteins (Proteins, Gene)FDA Link 10/2021 - 07/2014
7	Hyaluronic Acid (Hyaluronan)IBA 12/2022 - 11/2006
7	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2021 - 10/2004
7	ChemokinesIBA 05/2021 - 04/2002
6	CytokinesIBA 05/2022 - 04/2009
6	EnzymesIBA 10/2021 - 11/2006
6	GlycosaminoglycansIBA 09/2020 - 11/2004
5	Cadherins (E-Cadherin)IBA 10/2022 - 01/2007
5	Estrogens (Estrogen)FDA Link 01/2022 - 07/2014
5	Progesterone Receptors (Progesterone Receptor)IBA 01/2022 - 07/2014
5	Estrogen ReceptorsIBA 01/2022 - 06/2009
5	heparanaseIBA 07/2021 - 11/2006
5	IntegrinsIBA 01/2017 - 04/2002
5	DecorinIBA 05/2013 - 02/2005
4	Peptide Hydrolases (Proteases)FDA Link 05/2022 - 10/2004
4	Hormones (Hormone)IBA 11/2021 - 01/2013
4	Indicators and Reagents (Reagents)IBA 10/2021 - 09/2012
4	Syndecan-4IBA 10/2021 - 07/2007
4	LigandsIBA 05/2021 - 09/2006
4	Pharmaceutical PreparationsIBA 05/2020 - 02/2015
4	Biological ProductsIBA 12/2017 - 09/2006
3	SyndecansIBA 05/2022 - 04/2003
3	RNA-Binding Proteins (RNA-Binding Protein)IBA 03/2022 - 03/2020
3	Phenobarbital (Luminal)FDA Link 01/2022 - 01/2018
3	CollagenIBA 01/2021 - 07/2006
3	Estradiol (Delestrogen)FDA LinkGeneric 12/2017 - 04/2005
3	Protein Isoforms (Isoforms)IBA 12/2017 - 02/2015
3	Endothelin A ReceptorIBA 09/2010 - 04/2005
3	Endothelins (Endothelin)IBA 08/2010 - 04/2005
2	Syndecan-3IBA 05/2022 - 12/2009
2	ErbB Receptors (EGF Receptor)IBA 01/2022 - 08/2010
2	ResveratrolIBA 01/2022 - 01/2021
2	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2021 - 05/2013
2	SulfotransferasesIBA 01/2021 - 01/2020
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 01/2019
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 02/2015
2	Transforming Growth Factor beta (TGF-beta)IBA 10/2020 - 01/2019
2	Estrogen Receptor betaIBA 12/2017 - 06/2009
2	Estrogen Receptor alphaIBA 12/2017 - 06/2009
2	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2017 - 01/2010
2	Interleukin-6 (Interleukin 6)IBA 01/2017 - 05/2013
2	Dextrans (Dextran)FDA Link 01/2017 - 01/2010
2	OxazoloneIBA 12/2011 - 04/2009
2	Fulvestrant (Faslodex)FDA Link 09/2010 - 06/2009
2	Aromatase InhibitorsIBA 09/2010 - 06/2009
2	Endothelin-1 (Endothelin 1)IBA 09/2010 - 12/2007
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2010 - 08/2005
2	xylosylprotein 4-beta-galactosyltransferaseIBA 04/2008 - 07/2006
2	BiglycanIBA 07/2006 - 08/2005
1	Hyaluronan SynthasesIBA 12/2022
1	rho-Associated KinasesIBA 10/2022
1	Extracellular Matrix ProteinsIBA 05/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 05/2022
1	Cyclin-Dependent Kinase Inhibitor p21IBA 03/2022
1	EndometIBA 03/2022
1	Aurora Kinase AIBA 01/2022
1	Long Noncoding RNAIBA 01/2022
1	Growth Factor ReceptorsIBA 01/2022
1	GlypicansIBA 07/2021
1	Thromboplastin (Tissue Factor)IBA 05/2021
1	Zoledronic Acid (Zometa)FDA Link 01/2021
1	4-hydroxybenzyl alcoholIBA 01/2021

Therapy/Procedure

20	Therapeutics 01/2022 - 12/2007
8	Drug Therapy (Chemotherapy) 05/2022 - 01/2006
2	Neoadjuvant Therapy 07/2014 - 01/2006